Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02954536 · ClinicalTrials.gov registry record · Phase 2

Phase II Trial of Pembrolizumab With Trastuzumab and Chemotherapy in Advanced HER2 Positive Esophagogastric (EG) Cancer

A Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.

Completed
Registry status
Phase 2
Development phase
37
Enrollment target

NCT02954536: Completed Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.

NCT02954536 is a Phase 2 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 37 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (72% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT02954536, a Phase 2 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.

COMPLETED
Registry status
Phase 2
Development phase
37 participants
Enrollment target

Study Summary

The purpose of this study is to find out what effects, good and/or bad, pembrolizumab in combination with trastuzumab and chemotherapy, has on the patients' esophagogastric cancer.

Primary Outcome

We will define progression of disease per RECIST 1.1 criteria

Interventions

  • DRUG pembrolizumab
  • DRUG Oxaliplatin
  • DRUG cisplatin
  • DRUG trastuzumab
  • DRUG capecitabine

Trial Details

FieldValue
Enrollment Target 37 participants
Start Date 2016-11-03
Est. Completion 2023-03-14
Phase Phase 2
Memorial Sloan Kettering Cancer Center

1,884 total trials

What the finished NCT02954536 record still lists

NCT02954536 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 37 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (72% lower).

The record links to 0 conditions, and to 5 interventions - of which pembrolizumab is the first listed.

NCT02954536 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02954536 about?

NCT02954536 is a clinical study titled "Phase II Trial of Pembrolizumab With Trastuzumab and Chemotherapy in Advanced HER2 Positive Esophagogastric (EG) Cancer". The purpose of this study is to find out what effects, good and/or bad, pembrolizumab in combination with trastuzumab and chemotherapy, has on the patients' esophagogastric cancer.

What is the current status of trial NCT02954536?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 37 participants. The study started on 2016-11-03. Estimated completion is 2023-03-14.

What interventions are being tested in trial NCT02954536?

The interventions under investigation include: pembrolizumab (DRUG), Oxaliplatin (DRUG), cisplatin (DRUG), trastuzumab (DRUG), capecitabine (DRUG).

Who is sponsoring clinical trial NCT02954536?

This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.

Learn More About Clinical Trials

How this trial's enrollment target compares

Where NCT02954536's enrollment target sits among peer trials

37 1484th of 2000 higher than 505 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02800486 · 37 participants · Phase 2

    Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA

  • NCT03173937 · 37 participants · Phase 1

    Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome

  • NCT03295227 · 37 participants · Phase 1

    Pembrolizumab in Treating Participants With Unresectable Thymoma or Thymic Cancer

  • NCT03401047 · 37 participants · Early Phase 1

    Study to Assess Potential Impairments in Estradiol Augmentation of Gonadotropin Secretion in Polycystic Ovary Syndrome

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT02954536, the US trial registry maintained by the National Library of Medicine. NCT02954536 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.